We present here the first MS-case where rituximab-treatment led to grade IV neutropenia, with hospitalization and treatment of a serious infection with broad-spectrum antibiotics. The neutropenia resolved promptly with granulocyte-colony stimulating factor-treatment and the patient recovered well. Due to risk of recurring neutropenia rituximab-treatment was not re-administered. We discuss the mechanisms and occurrence of neutropenia as a side effect to rituximab-treatment of MS, and remind of the importance of monitoring rituximab-treated MS-patients for this rare but potentially dangerous side effect.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.msard.2017.12.005 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Late-onset Neutropenia after Rituximab Treatment for MPO-ANCA-associated Vasculitis.
Intern Med
July 2024
Department of Nephrology, Kurashiki Central Hospital, Japan.
Article Synopsis
- Rituximab, a medication often used in certain diseases, can lead to late-onset neutropenia (R-LON), a side effect that usually resolves without serious issues.
- A case study discusses a 91-year-old woman with kidney problems who developed febrile neutropenia 54 days after her last rituximab treatment for a specific type of vasculitis.
- The patient’s condition improved with treatment using granulocyte colony-stimulating factor and antibiotics, highlighting the potential dangers of R-LON in older adults or those with pre-existing health conditions.
Safety and efficacy of parsaclisib in combination with rituximab, bendamustine + rituximab, or ibrutinib in patients with previously treated B-cell lymphoma: analysis of a phase 1 dose-finding study (CITADEL‑112).
Leuk Lymphoma
July 2024
Clinic Barcelona, Barcelona, Spain.
Parsaclisib, a potent and highly selective phosphoinositide 3-kinase δ inhibitor, has shown clinical activity in relapsed/refractory (R/R) B-cell lymphoma. The phase 1 CITADEL-112 (NCT03424122) study assessed safety and efficacy of parsaclisib in combination with investigator choice standard of care (SOC; rituximab [Treatment A], rituximab plus bendamustine [Treatment B], or ibrutinib [Treatment C]) in 50 patients with R/R B-cell lymphoma. The most common treatment-emergent adverse events included neutropenia (62.
View Article and Find Full Text PDFMyelotoxicity and kidney dysfunction related to the use of trimethoprim-sulfamethoxazole for the treatment of Pneumocystis jirovecii pneumonia: a case report of severe adverse events with a common drug.
Rev Inst Med Trop Sao Paulo
March 2024
Instituto Estadual de Infectologia São Sebastião, Rio de Janeiro, Rio de Janeiro, Brazil.
Trimethoprim-sulfamethoxazole (TMP-SMX) is the primary therapeutic option for Pneumocystis jirovecii pneumonia (PCP). Gastrointestinal symptoms and cutaneous rash are common side effects, with hyperkalemia being uncommon in patients without kidney dysfunction, and myelotoxicity being even rarer. We present the case of a male patient with hypertension and a recent diagnosis of non-Hodgkin lymphoma, undergoing rituximab treatment for two months.
View Article and Find Full Text PDFNeutropaenia complications from Ocrelizumab and Rituximab treatment.
Mult Scler Relat Disord
January 2024
Department of Neuroscience Monash University, Melbourne, Australia; Department of Neurology, Alfred Hospital, Melbourne, Australia; Department of Neurology, Royal Melbourne Hospital, Melbourne, Australia. Electronic address:
Ocrelizumab is an anti-CD20 monoclonal antibody (mAb) that has been shown in phase 3 clinical trials to reduce relapses and disease progression in multiple sclerosis (MS) patients. Prior to the approval of ocrelizumab, rituximab, a chimeric anti-CD20 mAb was used to treat MS. Rituximab is still used to treat MS in many countries outside of Australia and remains mainstay of treatment of many non-MS neuroimmunological and systemic inflammatory diseases.
View Article and Find Full Text PDFObinutuzumab in Frequently Relapsing and Steroid-Dependent Nephrotic Syndrome in Children.
Clin J Am Soc Nephrol
December 2023
Pediatric Nephrology Department, Robert-Debré Hospital, APHP, Paris, France.
Background: B-cell depletion with rituximab induces sustained remission in children with steroid-dependent or frequently relapsing nephrotic syndrome. However, most patients relapse after B-cell recovery, and some patients do not achieve B-cell depletion. Obinutuzumab is a second-generation anti-CD20 antibody designed to overcome such situations in B-cell malignancies and was recently reported to be safe and effective in other autoimmune diseases affecting the kidneys.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!